Background
Methods
CDDP group (n = 38) | THD group (n = 30) | p | |
---|---|---|---|
Male/females | 25/13 | 19/11 | |
Age, years | 64.5 ± 13.2 | 65.2 ± 11 |
0.82
|
Body weight (kg) | 65.5 ± 15.1 | 66.2 ± 11.9 |
0.73
|
BMI (kg/m2) | 23.7 ± 4.0 | 25.6 ± 4.13 |
0.03
|
Urine volume output (mL/24 h) | 1983 ± 651 | 1472.6 ± 433 |
<0.001
|
GFR (mL/min × 1.73 mq b.s) | 7.8 ± 1.9 | 9.2 ± 4.2 |
<0.01
|
EPO (IU/kg/week) | 104 ± 108 | 184 ± 84 |
<0.001
|
CRP <5 mg/dl, % | 89 | 66.6 |
<0.01
|
iPTH, >300 ρg/mL, % | 31.5 | 50 |
<0.01
|
Charlson comorbidity index score | 5.5 ± 2.5 | 3.8 ± 2.5 |
0.004
|
Charlson comorbidity index score >4, % | 62.5 | 33.3 |
<0.01
|
Statistical analysis
Results
CDDP group | THD group | ||||||
---|---|---|---|---|---|---|---|
Baseline (n = 38) | 6 months (n = 38) | 12 months (n = 34) | Baseline (n = 30) | 6 months (n = 30) | 12 months (n = 29) |
P
| |
Dry weight (kg)
|
65 ± 15.0
|
63.9 ± 14.4
|
63.4 ± 14.7
|
66.2 ± 11.9
|
64.9 ± 11.5
|
65.5 ± 12.3
|
0.07
|
BMI (kg/m
2
)
|
23.7 ± 4.0
|
23.4 ± 3.7
|
23.0 ± 3.9
|
25.6 ± 4.13
|
25.1 ± 4.07
|
25.4 ± 4.2
|
0.07
|
Total body water (L)
|
44.4 ± 10.5
|
41 ± 9.6
|
43 ± 11
|
35.4 ± 6
|
33.5 ± 5.8
a
|
33.8 ± 5.9
a
|
0.02
|
Extracellular water (L)
|
20 ± 4.5
|
18.6 ± 4.3
|
19.7 ± 4
|
17.5 ± 3.2
|
16 ± 2.8
b
|
15.7 ± 2.4
b
|
0.04
|
Fat mass (kg)
|
11 ± 12.3
|
13 ± 11.8
|
11.4 ± 11
|
20 ± 9
|
21.4 ± 8.5
|
22.6 ± 9.4
|
0.03
|
Body cell mass (kg)
|
31 ± 9.6
|
28 ± 8.9
|
29.7 ± 10.3
|
22.5 ± 6.2
|
22.7 ± 5
|
22.7 ± 5.8
|
0.02
|
Phase angle, (°)
|
6.2 ± 1.3
|
6.2 ± 1.3
|
6.1 ± 1.4
|
5.0 ± 1.2
|
6 ± 0.9
|
5.8 ± 1.2
|
0.06
|
SBP (mmHg)
|
139 ± 18
|
132 ± 20
|
128 ± 15
b
|
136.8 ± 17.2
|
138.5 ± 18.5
|
139 ± 20.8
|
0.21
|
DBP (mmHg)
|
80 ± 12
|
73 ± 10
|
74 ± 9
c
|
71.6 ± 11.4
|
71.6 ± 10
|
72.9 ± 12.3
|
0.08
|
Serum creatinine (mg/dL)
|
6.4 ± 1.9
|
7.0 ± 2.5
|
7.8 ± 3.0
b
|
5.9 ± 1.8
|
7.8 ± 2.2
|
8.2 ± 2.4
b
|
0.05
|
B.U.N. (mg/dL)
|
68 ± 18
|
68 ± 16
|
70 ± 17
|
84.4 ± 18.5
|
77 ± 15.5
|
77 ± 22.9
|
0.003
|
GFR (mL/min)
|
7.8 ± 1.9
|
6.7 ± 2.3
|
6.3 ± 2.1
b
|
9.2 ± 4.2
|
-
|
-
|
-
|
eGFR (mL/min)
|
9.4 ± 2.9
|
8.4 ± 3.5
a
|
8.0 ± 3.4
b
|
10.3 ± 3.9
|
-
|
-
|
-
|
Total protein (g/dL)
|
6.7 ± 0.5
|
6.7 ± 0.5
|
6.8 ± 0.4
|
6.35 ± 0.52
|
6.4 ± 0.5
|
6.5 ± 0.43
|
0.004
|
Albumin (g/dL)
|
3.8 ± 0.4
|
3.9 ± 0.4
|
4.1 ± 0.4
b
|
3.6 ± 0.40
|
3.6 ± 0.37
|
3.7 ± 0.48
|
0.01
|
Transferrine (mg/dL)
|
219 ± 53
|
203 ± 72
|
222 ± 53
|
264 ± 94
|
249 ± 43
|
251 ± 61
|
0.001
|
C3 (mg/dL)
|
90 ± 20
|
91 ± 23
|
94 ± 23
|
99.6 ± 39.6
|
96 ± 35.7
|
95.9 ± 32
|
0.48
|
C4 (mg/dL)
|
24 ± 7
|
24 ± 8
|
26 ± 7
|
33 ± 28
|
29 ± 18
|
29 ± 30
|
0.26
|
Total IgG (mg/dL)
|
1599 ± 497
|
1590 ± 402
|
1543 ± 373
|
1440 ± 461
|
1482 ± 487
|
1409 ± 413
|
0.21
|
Lynphocytes/mm
3
|
1539 ± 651
|
1390 ± 831
|
1581 ± 537
|
1452 ± 811
|
1458 ± 622
|
1445 ± 580
|
0.38
|
CDDP group | THD group | ||||||
---|---|---|---|---|---|---|---|
Baseline (n = 38) | 6 months (n = 38) | 12 months (n = 34) | Baseline (n = 30) | 6 months (n = 30) | 12 months (n = 29) | P | |
Triglycerides (mg/dL)
| 109 ± 36 | 134 ± 92 | 126 ± 50 | 131 ± 72 | 152 ± 67 | 139 ± 52 |
0.03
|
Total Cholesterol (mg/dL)
| 164 ± 36 | 168 ± 36 | 164 ± 35 | 165 ± 41 | 168.5 ± 34 | 170 ± 40 |
0.51
|
HDL Cholesterol (mg/dL)
| 44 ± 14 | 47 ± 13 | 48 ± 20 | 44 ± 12 | 45 ± 13 | 44 ± 12 |
0.58
|
LDL Cholesterol (mg/dL)
| 101 ± 29 | 93 ± 34 | 93 ± 31 | 95 ± 32 | 93 ± 29 | 97.8 ± 34 |
0.95
|
Cholinesterases (UI/mL)
| 5474 ± 1396 | 6073 ± 1474 | 586 ± 1646 | 4968 ± 1488 | 5511 ± 1604 | 4673 ± 1450b
|
0.27
|
Uric acid (mg/dL)
| 7.3 ± 2.3 | 7.5 ± 2.4 | 7.1 ± 1.9 | 6.4 ± 1.8b
| 7.3 ± 1.2 | 7.2 ± 1.3b
|
0.60
|
Sodium (mmol/L)
| 139 ± 2.6 | 137 ± 3.6 | 137 ± 4.0 | 138 ± 2.7 | 138 ± 2.3 | 134 ± 3.3 |
0.58
|
Potassium (mmol/L)
| 4.4 ± 0.6 | 4.3 ± 0.6 | 4.3 ± 0.7 | 4.3 ± 0,67 | 4.7 ± 0.7 | 4.8 ± 0.9b
|
0.07
|
Calcium (mg/dL)
| 9.2 ± 0.5 | 9.0 ± 0.5 | 9.1 ± 0.6 | 9.1 ± 0.6 | 9.1 ± 0.7 | 9.0 ± 0.5 |
0.51
|
Phosphatemia (mg/dL)
| 4.4 ± 0.9 | 4.6 ± 0.8 | 4.6 ± 0.8 | 5.1 ± 1.5 | 5.6 ± 1.1 | 5.2 ± 1.1 |
0.001
|
Bicarbonate (mEq/L)
| 22.0 ± 3.1 | 23.1 ± 3.3 | 23.2 ± 3.2 | 21.8 ± 4.2 | 21.9 ± 3.2 | 21.6 ± 2.7 |
0.17
|
β2-microglobulin (mg/dL)
| 14.2 ± 3.9 | 16.8 ± 5.7 | 16.0 ± 5.1 | 18.4 ± 11.6 | 31.0 ± 16.0 | 28.0 ± 11.4b
|
0.007
|
Hb (g/dl)
| 10.8 ± 0.1 | 11.5 ± 0.95 | 11.5 ± 0.97a
| 10.5 ± 1.4 | 11.3 ± 0.9 | 11.2 ± 0.95a
|
0.31
|
EPO (IU/kg/week) | 104 ± 108 | 69 ± 59 | 60 ± 74b
| 184 ± 84 | 172 ± 138 | 204 ± 252 |
0.002
|
ERI (IU/kg/week)/Hb | 10 ± 11 | 6 ± 5 | 5 ± 7b
| 19 ± 10 | 15 ± 13 | 19 ± 23 |
<0.001
|
CRP (% patients) <5.0
| 89 | 81.5 | 79 | 66.6 | 83.3 | 76.6 |
<0.05
|
CRP (mg/dL)
| 3.3 ± 3.9 | 3.5 ± 3.3 | 3.2 ± 3.6 | 8.6 ± 9.7 | 4.9 ± 6.5 | 5.8 ± 5.8 |
<0.01
|
iPTH (ρg/mL) <150 (%)
| 39.5 | 52.6 | 52 | 36.7 | 43.3 | 34.5 |
0.09
|
iPTH (ρg/mL) 150–300 (%)
| 29 | 29 | 30 | 13.3 | 20 | 27.6 |
0.26
|
iPTH (ρg/mL) >300 (%)
| 31.5a
| 18.4 | 18a
| 50 | 36.7 | 37.9 |
0.02
|
CDDP Group | THD group | P | |||
---|---|---|---|---|---|
% of patients | Baseline | 12 months | Baseline | 12 months | |
ACEi
| 34 | 33 | 50 | 48.3 |
n.s
|
ARBs
| 24 | 26 | 30 | 21 |
n.s
|
Calcium channel blockers
| 28.9 | 27.3 | 30 | 17 |
n.s
|
Calcium carbonate
| 59 | 60 | 76.6 | 72.4 |
n.s.
|
Sevelamer or Lanthanum carbonate
| 0 | 12a
| 0 | 41c
|
<0.03
|
Paricalcitol
| 0 | 12b
| 0 | 17.2b
|
n.s.
|
Cinacalcet
| 0 | 6b
| 0 | 24c
|
<0.04
|
Calcitriol
| 45 | 42 | 46.7 | 45 |
n.s.
|
Kayexalate
| 21 | 21 | 20 | 38 |
n.s.
|
Allopurinol
| 48.6 | 54 | 33.3 | 13.8a
|
0.01
|
Statins
| 37 | 33 | 26.7 | 24 |
n.s
|
Polyunsaturated fats
| 13 | 9 | 10 | 17 |
n.s.
|